ADRIATIC Trial: Durvalumab, cCRT Timing, and Survival in LS-SCLC

Author(s):

Ticiana A. Leal, MDAnne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital

Panel experts analyze findings from the phase 3 ADRIATIC trial, examining overall and progression-free survival data, exploring the interaction between durvalumab and concurrent chemoradiotherapy within the tumor microenvironment, and evaluating the impact of time intervals from the completion of concurrent chemoradiotherapy to the initiation of consolidation therapy with a PD-L1 inhibitor.

EP: 1.Optimizing First-Line Therapy for Limited-Stage Small Cell Lung Cancer

Now Viewing

EP: 2.ADRIATIC Trial: Durvalumab, cCRT Timing, and Survival in LS-SCLC

Please discuss results from the phase 3 ADRIATIC trial, evaluating durvalumab in patients with LS-SCLC who did not have disease progression following concurrent chemoradiotherapy (cCRT) vs placebo after cCRT. (Spigel D, et al. Plenary Session 2024 ASCO Annual Meeting. LBA5.)
How might the statistically significant overall survival and progression-free survival outcomes reported in ADRIATIC translate to clinically relevant improvement in life expectancy of your patients with limited-stage SCLC?
What are the mechanisms by which durvalumab synergizes with concurrent chemoradiotherapy within the tumor microenvironment?
In patients with LS-SCLC, what would you consider to be a reasonable time interval between completion of cCRT to initiation of consolidation therapy with a PD-L1 inhibitor?
1. Please discuss your thoughts on the range of time prior to initiating therapy - from immediately to 6 weeks post-cCRT.
What is the potential for curative-intent immunotherapy with durvalumab for earlier stages of SCLC?
1. What is the role of SBRT in earlier stages of disease vs cCRT followed by durvalumab?